JP2024501051A5 - - Google Patents

Info

Publication number
JP2024501051A5
JP2024501051A5 JP2023539796A JP2023539796A JP2024501051A5 JP 2024501051 A5 JP2024501051 A5 JP 2024501051A5 JP 2023539796 A JP2023539796 A JP 2023539796A JP 2023539796 A JP2023539796 A JP 2023539796A JP 2024501051 A5 JP2024501051 A5 JP 2024501051A5
Authority
JP
Japan
Prior art keywords
dosage form
solid dosage
sustained
upadacitinib
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/065443 external-priority patent/WO2022147073A1/en
Publication of JP2024501051A publication Critical patent/JP2024501051A/ja
Publication of JP2024501051A5 publication Critical patent/JP2024501051A5/ja
Pending legal-status Critical Current

Links

JP2023539796A 2020-12-29 2021-12-29 持続放出ウパダシチニブ配合物 Pending JP2024501051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131564P 2020-12-29 2020-12-29
US63/131,564 2020-12-29
PCT/US2021/065443 WO2022147073A1 (en) 2020-12-29 2021-12-29 Extended release upadacitinib formulations

Publications (2)

Publication Number Publication Date
JP2024501051A JP2024501051A (ja) 2024-01-10
JP2024501051A5 true JP2024501051A5 (enExample) 2025-01-07

Family

ID=82261098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539796A Pending JP2024501051A (ja) 2020-12-29 2021-12-29 持続放出ウパダシチニブ配合物

Country Status (8)

Country Link
US (3) US20240316040A1 (enExample)
EP (1) EP4271380A4 (enExample)
JP (1) JP2024501051A (enExample)
KR (1) KR20230127266A (enExample)
AU (1) AU2021411506A1 (enExample)
CA (1) CA3206839A1 (enExample)
MX (1) MX2023007741A (enExample)
WO (1) WO2022147073A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
EP4583877A1 (en) * 2022-09-09 2025-07-16 Intas Pharmaceuticals Ltd. Upadacitinib formulation
CN117357492A (zh) * 2023-10-31 2024-01-09 苏州天马医药集团天吉生物制药有限公司 一种乌帕替尼缓释片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003453A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Barra de empuje oros para el suministro controlado de agentes activos.
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
AU2018312349A1 (en) * 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib

Similar Documents

Publication Publication Date Title
JP2024501051A5 (enExample)
CN102858373B (zh) 易服用性固体制剂
US20020086056A1 (en) Tablet containing a coated core
JP2016006108A5 (enExample)
JP2009545560A5 (enExample)
JP2016199602A5 (enExample)
US20100247647A1 (en) Sustained release tablets with hydromorphone
WO2008142627A2 (en) Multilayered modified release formulation comprising amoxicillin and clavulanate
JP2010163455A (ja) 活性成分放出制御薬物製剤
HRP20110739T1 (hr) Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem lijeka u tankom crijevu i postupak njegovog dobivanja
EP4159203A1 (en) Oral sustained-release composition for insoluble drug, and preparation method thereof
US20250161302A1 (en) Extended release upadacitinib formulations
US20110052687A1 (en) Extended release pharmaceutical composition of paliperidone
US20120258173A1 (en) Functionally-Coated Multilayer Tablets
US20030099710A1 (en) Granule modulating hydrogel system
CA2529393C (en) Sustained release formulation for venlafaxine hydrochloride
CN102091053B (zh) 一种颗粒组合控释片
HRP20240303T1 (hr) Osmotski oblici doziranja koji sadrže deutetrabenazin i postupci njihove upotrebe
KR100745515B1 (ko) 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
KR20230071723A (ko) 산 민감성 성분을 포함하는 삼투성 제제 조성물
WO2007015270A2 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
WO2007017219A2 (en) Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
US20040228918A1 (en) Granule modulating hydrogel system
US20070087056A1 (en) Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
EP3331505B1 (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof